Targeted therapy is at the heart of our pipeline
Tolero has a pathway-centric pipeline of investigational agents aimed at targeting abnormalities in cell function in the context of pathway inhibition. Our approach is to develop specific inhibitors of signaling pathways and identify diseases dependent on these pathways.Learn More
Late-stage investigations of targeted therapy
Zella 201 is a clinical trial of alvocidib in combination with cytarabine and mitoxantrone (ACM), in adult patients with relapsed or refractory acute myeloid leukemia (AML).Learn More
Understanding leukemic blast survival through MCL-1 and CDK9 activity
In this target-driven era of treatment for hematologic malignancies, understanding the distinguishing characteristics of leukemic blast subsets* may be a clinical necessity.
*The prevalence of MCL-1–dependent hematologic malignancies is being investigated.